VP, Chief Product Security Officer, Illumina
Oleg Yusim
Cybersecurity expectations for medical devices just shifted again. On June 27, 2025, the FDA issued its updated Cybersecurity in Medical Devices guidance, expanding requirements for “cyber devices,” clarifying FDORA §524B obligations, and reinforcing expectations around SBOMs, vulnerability disclosure, and update planning.
If you’ve already been working to meet the FDA’s 2023 requirements, you may be asking: What’s different this time? Where has the FDA provided more clarity? And how can you demonstrate “reasonable assurance of cybersecurity” in a world where software-driven devices now operate as part of larger digital ecosystems that include mobile apps, cloud services, and connected care platforms?
Orthogonal and a panel of experts discussed what’s new in the 2025 guidance, compare it to the 2023 version, and provide practical insights you can apply directly to your regulatory and engineering strategies.
VP, Chief Product Security Officer, Illumina
Oleg Yusim
Founder, Blue Goat Cyber
Christian Espinosa
VP of Regulatory & Quality, Orthogonal
Megan Graham
Founder & CEO, Orthogonal
Bernhard Kappe
Related Posts
Talk
Medical Device Manufacturers as Providers: A New and Emerging MedTech Model
Talk
Leveraging Automation to Deliver High-Quality MedTech Software
Talk
The Playbook for Running a Multi-Partner Engineering Organization
Talk
Bridging the Gap: SaMD Strategy for Teams Built on Hardware